Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

Exclusion Criteria

• •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, hepatic, psychiatric, neurological, dermatological, or allergic disease;
• •Medical history of T2DM (for non-diabetic obese participants, if enrolled);
• •Diagnosis of type 1 diabetes mellitus or secondary forms of diabetes;
• •Evidence or history of clinically significant cardiovascular disease;
• •Any malignancy not considered cured;
• •Acute pancreatitis or history of chronic pancreatitis;
• •Acute gallbladder disease;
• •Any condition possibly affecting drug absorption;
• •Personal or family history of MTC or MEN2;
• •Medical or psychiatric condition that may increase the risk of study participation;
• •Any vaccination within the 1 week prior to admission to the CRU;
• •Previous administration with an investigational drug within 30 days or 5 half-lives preceding first dose;
• •Known prior participation in a trial involving PF-07081532;
• •A positive urine drug screen at screening or admission;
• •Positive testing at screening for HIV, HBsAg, HBcAb, HBsAb or HCVAb;
• •Positive COVID-19 test at screening or admission;
• •Supine BP ≥160 mm Hg (systolic) or ≥100 mm Hg (diastolic);
• •12-lead ECG clinically relevant abnormalities that may affect participant safety or interpretation of study results;
• •Participants with ANY of the following abnormalities in clinical laboratory tests: \*AST or ALT level ≥1.5x ULN;
• •* Total bilirubin level ≥1.5x ULN;
• •* TSH\> ULN;
• •* Fasting C-peptide \<0.8 ng/mL;
• •* Serum calcitonin \> ULN;
• •* Amylase \> ULN;
• •* Lipase \> ULN;
• •* eGFR \<60 mL/min/1.73m2 (per MDRD equation);
• •* FPG \>270 mg/dL
• •History of alcohol abuse, binge drinking and/or any illicit drug use or dependence within 6 months of Screening;
• •Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing;
• •History of sensitivity to heparin or heparin induced thrombocytopenia;
• •Known intolerance to any GLP-1R agonist.